Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50—59 Years - Schmader, Kenneth E.; Levin, Myron J.; Gnann, John W.; McNeil, Shelly A.; Vesikari, Timo; Betts, Robert F.; Keay, Susan; Stek, Jon E.; Bundick, Nickoya D.; Su, Shu-Chih; Zhao, Yanli; Li, Xiaoming; et al. (Clinical infectious diseases, 2012)
Keywords: Acute pain; Age groups; and Commentaries; ARTICLES AND COMMENTARIES; Biological and medical sciences; Clinical trials; Disease prevention; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions - epidemiology; Europe - epidemiology; Female; Herpes viruses; Herpes zoster; Herpes Zoster - epidemiology; Herpes Zoster - prevention & control; Herpes zoster vaccine; Herpes Zoster Vaccine - administration & dosage; Herpes Zoster Vaccine - adverse effects; Herpes Zoster Vaccine - immunology; Human viral diseases; Humans; Immune response; Immunization; Incidence; Infectious diseases; Male; Medical sciences; Middle Aged; North America - epidemiology; Older adults; Pain; Placebos; Placebos - administration & dosage; Polymerase chain reaction; Postherpetic neuralgia; Vaccination; Vaccines; Viral diseases; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye; North America; Europe; Infection; Prevention; Immunoprophylaxis; Skin disease; Nervous system diseases; Herpes zoster; Viral disease; Vaccine